Detail of the clinical trial
| Title of the trial | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas |
|---|---|
| EudraCT number | 2012-004034-42 |
| Protocol number | GS-US-313-0125 |
| Sponsor | Gilead Sciences, Inc.,333 Lakeside Drive, Foster City, California 94404, United States |
| Indications | Oncology |
| Diagnosis | Indolent Non-Hodgkin Lymphomas |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2013 |
| Date of approval by Institute (SÚKL) | 28.8.2013 |
| Date of approval by EC | 27.6.2013 |
| Date of initiation CT in ČR | 2.12.2013 |
| Date of ending CT in ČR | 11.3.2016 (7.3.2016) |
| Notice | |
| Sites |
Fakultní nemocnice Brno,,Jihlavská 20,Brno,625 00 Fakultní nemocnice Hradec Králové,,Sokolská 581,Hradec Králové,500 05 Fakultní nemocnice Ostrava ,,17. listopadu 1790,Ostrava,708 52 |
cz